The antianginal ranolazine mitigates obesity-induced nonalcoholic fatty liver disease and increases hepatic pyruvate dehydrogenase activity
Rami Al Batran(Art Research Centre of the Slovak Academy of Sciences), John R. Ussher(University of Alberta)
Cited by 18
Related Papers
Cardiac-Specific Deletion of Pyruvate Dehydrogenase Impairs Glucose Oxidation Rates and Induces Diastolic Dysfunction
|Frontiers in Cardiovascular Medicine|2018|42